Earlier Meningitis Vaccine Booster May be Necessary for CAD Patients on Anti-complement Therapy, Study Suggests
To lower the risk of meningitis infection in patients with cold agglutinin disease (CAD) treated with Soliris (eculizumab), a booster given shortly after the first vaccination may be required, a study suggests. Because patients who receive therapies that target the complement system — such as Soliris — are…